StemCells, Inc. to Participate at the 13th Annual Needham Healthcare Conference

StemCells, Inc. to Participate at the 13th Annual Needham Healthcare
Conference

Management Will Present an Update on the Company's Programs, Pipeline and
Operations

NEWARK, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM) announced today that management will present at the 13th Annual
Needham Healthcare Conference, on Wednesday, April 9, at 8:40 AM EDT at the
Westin Grand Central Hotel, 212 East 42nd Street, in New York City. Management
is scheduled to present an update on the Company's programs, pipeline and
operations.

A live webcast of the presentation will be available through the Company's
corporate website: http://www.stemcellsinc.com. Interested parties are
encouraged to connect to the website at least 15 minutes prior to the
presentation to ensure adequate time for any software downloads that may be
necessary. The webcast can be accessed through the following link:
http://wsw.com/webcast/needham65/stem.

A replay will also be accessible for 90 days through the Company's website.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's platform technology, HuCNS-SC® cells (purified
human neural stem cells), are currently in development as a potential
treatment for a broad range of central nervous system disorders. In a Phase I
clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination
disorder in children, the Company has shown preliminary evidence of
progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland, Canada and the
United States, and has reported positive interim data for the first three
patients. The Company is also conducting a Phase I/II clinical trial in dry
age-related macular degeneration (AMD) in the United States. In addition, the
Company is pursuing preclinical studies in Alzheimer's disease, with support
from the California Institute for Regenerative Medicine (CIRM). StemCells also
markets stem cell research products, including media and reagents, under the
SC Proven® brand. Further information about StemCells is available at
http://www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein. These
forward-looking statements speak only as of the date of this news release. The
Company does not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date hereof. Such
statements reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The Company's actual
results may vary materially from those contemplated in such forward-looking
statements due to risks and uncertainties to which the Company is subject,
including those described under the heading "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2013 and in its
subsequent reports on Forms 10-Q and 8-K.

CONTACT: Greg Schiffman
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
        
         Andrea Flynn
         Russo Partners
         (646) 942-5631

company logo
 
Press spacebar to pause and continue. Press esc to stop.